Intravenous (IV) Ibuprofen Market Report 2026

The intravenous (iv) ibuprofen market size has grown rapidly in recent years. It will grow from $9.37 billion in 2025 to $10.51 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing postoperative pain management needs, widespread use of NSAIDs in hospital settings, growth in surgical procedure volumes, rising incidence of acute inflammatory conditions, established clinical efficacy of ibuprofen for pain and fever.

The intravenous (iv) ibuprofen market size is expected to see rapid growth in the next few years. It will grow to $16.41 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to growing demand for opioid-sparing pain management strategies, increasing adoption of iv therapies in ambulatory surgical centers, rising pediatric and geriatric hospitalization rates, expansion of acute care infrastructure, growing preference for fast-onset analgesic treatments. Major trends in the forecast period include growing adoption of iv ibuprofen for postoperative pain management, increasing use of non-opioid analgesics in acute care settings, rising preference for rapid-acting injectable pain therapies, expansion of iv ibuprofen use in pediatric and critical care, increasing availability of high-concentration iv ibuprofen formulations.

The increasing prevalence of pain disorders is anticipated to drive the growth of the intravenous ibuprofen market in the coming years. Pain disorders are medical conditions marked by persistent or chronic pain that interferes with daily activities, often resulting from nerve, musculoskeletal, or inflammatory issues. This rise in pain disorders is largely attributed to the aging population, as older adults are more susceptible to chronic conditions such as arthritis, osteoarthritis, and nerve pain, thereby increasing the demand for effective pain relief. Intravenous ibuprofen aids in pain management by delivering rapid relief, making it suitable for acute and postoperative pain. It alleviates inflammation and enhances patient comfort, improving treatment outcomes in clinical settings. For example, in January 2024, data from the Office for Health Improvement and Disparities, a UK government department, indicated that the percentage of individuals aged 16 and older who self-reported a long-term musculoskeletal condition increased to 18.4% in 2023, up from 17.6% in 2022. Consequently, the growing prevalence of pain disorders is fueling the expansion of the intravenous ibuprofen market.

Major companies in the intravenous ibuprofen market are focusing on developing advanced drug formulations, such as opioid-free analgesics, to improve pain management while reducing opioid dependency. An opioid-free analgesic is a pain-relieving medication that does not contain opioids, thereby avoiding the risk of addiction and opioid-related side effects. For example, in February 2024, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched COMBOGESIC IV (acetaminophen and ibuprofen) injection in the US, following Food and Drug Administration (FDA) approval in October 2023. This intravenous, opioid-free analgesic is indicated for mild to moderate pain relief and can also be used as an adjunct for moderate to severe pain management. By combining two active ingredients with different mechanisms, COMBOGESIC IV offers a novel, non-opioid pain management option for healthcare providers.

In May 2024, Halex Istar Industria Farmaceutica SA, a Brazil-based pharmaceutical company, partnered with AFT Pharmaceuticals Ltd. This partnership focuses on expanding the distribution of Maxigesic IV (paracetamol + ibuprofen IV) in Brazil, providing effective non-opioid pain management solutions. AFT Pharmaceuticals Ltd is a New Zealand-based pharmaceutical company specializing in intravenous pain relief.

Major companies operating in the intravenous (iv) ibuprofen market are Pfizer Inc., Sanofi S.A., Novartis AG, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Baxter International, Mylan N.V., Sandoz Group AG, Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, Eurolife Healthcare Pvt. Ltd., B. Braun Holding GmbH & Co. KG, AFT Pharmaceuticals Ltd, Cumberland Pharmaceuticals Inc., Delex Pharma International Inc., Xgen Pharmaceuticals Djb Inc., Wellona Pharma, Hyloris Pharmaceuticals SA.

North America was the largest region in the intravenous (IV) ibuprofen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous (iv) ibuprofen market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous (iv) ibuprofen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the intravenous ibuprofen market by increasing the cost of imported active pharmaceutical ingredients, sterile packaging materials, and injectable drug manufacturing components. These impacts are most pronounced in hospitals and ambulatory surgical centers, particularly in north america and europe where dependence on global pharmaceutical supply chains is high. Elevated tariffs have led to higher production and procurement costs. However, they have also encouraged domestic manufacturing, supply chain localization, and process optimization, supporting long-term supply security and cost stability.

The intravenous (iv) ibuprofen market research report is one of a series of new reports that provides intravenous (iv) ibuprofen market statistics, including intravenous (iv) ibuprofen industry global market size, regional shares, competitors with a intravenous (iv) ibuprofen market share, detailed intravenous (iv) ibuprofen market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous (iv) ibuprofen industry. This intravenous (iv) ibuprofen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intravenous (IV) ibuprofen is a form of ibuprofen delivered directly into the bloodstream through an intravenous route. Its primary purpose is to provide rapid pain relief and reduce inflammation or fever, particularly in patients who are unable to take oral medications. It functions by inhibiting the production of prostaglandins, which are responsible for pain and inflammation. Intravenous ibuprofen is frequently used for postoperative pain and acute conditions that require fast relief.

The main product types in the intravenous (IV) ibuprofen market include conventional intravenous (IV) ibuprofen and high-concentration intravenous (IV) ibuprofen. Conventional intravenous (IV) ibuprofen refers to the standard formulation of ibuprofen administered directly into the bloodstream via an IV to relieve pain, reduce inflammation, and manage fever, typically in hospital settings for acute or postoperative pain. Available strengths of intravenous ibuprofen include 100 mg, 200 mg, 400 mg, and 800 mg. It is used across various age groups, including both pediatrics and adults. The primary applications of IV ibuprofen are for pain, fever, inflammation, and other related conditions. Key end-users include hospitals, ambulatory surgical centers, clinics, and other healthcare facilities.

The intravenous (IV) ibuprofen market consists of sales of pediatric intravenous (IV) ibuprofen, intravenous (IV) ibuprofen concentrate and pre-mixed intravenous (IV) ibuprofen bags. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.